Wordt geladen...
Why Do So Many Drugs for Alzheimer's Disease Fail in Development? Time for New Methods and New Practices?
Alzheimer's disease (AD) drug developments and clinical trials (CT) remain vulnerable to problems that undermine research validity. Investigations of CT methods reveal how numerous factors decrease active drug-placebo group differences and increase variance, thereby reducing power to reach stat...
Bewaard in:
| Hoofdauteurs: | , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2008
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3372084/ https://ncbi.nlm.nih.gov/pubmed/18953116 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|